Laqininimod, a pill from Teva Pharmaceuticals has shown enough promise and safety in the treatment of relapsing remitting multiple sclerosis that the manufacturer is now preparing the product for a phase 3 study. No oral disease modifying therapy has made it past this phase in the drug trial stages, although a “cousin” of Laquinimod did survive until phase 3 when the drug was discovered to have adverse effects on the heart.

Microsoft has a column with tips for persons with multiple sclerosis that can enable them to use Microsoft Office products more effectively.

MyMSmyWay has links to freeware and other suggestions for making life with you computer more productive.